Scaling Production of Cultured THCV with Cronos Group

Cronos and Ginkgo Announce Achievement of THCV Equity Milestone

Today, we’re excited to announce an achievement in our partnership with Cronos Group, an innovative global cannabinoid company. Together, we have hit the third target productivity milestone in our partnership to produce eight cultured cannabinoids. Using our platform for organism design and development, Cronos has successfully achieved the productivity target for tetrahydrocannabivarin (THCV), a cannabinoid hypothesized to reduce the appetite-enhancing property of THC. Access to additional rare cannabinoids will support Cronos’ innovation pipeline and commercialization strategy.

Our partnership with Cronos launched in 2018, with the goal of accessing rare molecules in the cannabis plant to create innovative and differentiated products that would otherwise be cost-prohibitive. The program combines Cronos’ deep understanding of the biological structure and function of cannabinoids with our vast experience designing microorganisms for the production of cultured products across pharmaceuticals, agriculture and more.

Producing cultured cannabinoids at industrial scale

“Continuing to hit these productivity milestones in partnership with Ginkgo fuels our innovation pipeline focused on creating borderless products utilizing rare cannabinoids that amplify and differentiate the consumer experience,” said Mike Gorenstein, Chairman, President and CEO of Cronos. “We are excited about the possibilities that THCV is expected to give us and look forward to getting more products with rare cannabinoids into market.”

Working with Cronos to develop innovations in cannabis is an opportunity for us to apply synthetic biology in a way that is helping bring the cannabis industry forward and make a real impact on its market and the customers it serves. The progress we’ve made thus far in our collaboration is a true testament to both the potential of synthetic biology and the world-class teams at Cronos and Ginkgo.

Find the full press release here along with all of the latest news from the Ginkgo team.

What will you grow with Ginkgo?

Synthetic Biology for Climate Action

We believe synthetic biology has an important role to play in addressing climate change.

Climate change is a global threat that requires immediate action. It’s already impacting every single person and living thing on our planet. The best time to address climate change was decades ago; the next best time? Now. So, what are we waiting for? Let’s go grow!

Limiting warming to below 1.5°C will require us to reimagine our industrial landscapes to eliminate emissions and to sequester carbon from the atmosphere. Decarbonizing our energy, materials, chemicals, and food production will require massive shifts in how we make stuff.

We believe that synthetic biology has an important role to play in this climate transition, whether it’s the resilience of ecosystems and communities to a changing climate, the reduction of emissions through circular manufacturing, or the sequestration of carbon through soil, oceanic, lithospheric, or anthropogenic sinks. We believe synthetic biology is going to be one of the enabling technologies for this revolution.

Biology is natively the technology of climate: it makes our air, makes our food, and cleans our water. We believe the ability to engineer biology is ultimately the biggest climate technology in the world.

What are we waiting for? Let’s go grow!

Last week, we hosted a virtual event with several key thought leaders in the world of synthetic biology for climate tech. Over 650 people from the wider synthetic biology and climate tech communities tuned in to share their work and excitement. The panelists discussed carbon fixation and sequestration pathways, manufacturing scale up, and new business models for carbon capture. You can check out the recording of the main stage above or on Ginkgo’s YouTube channel.

Bill Gates recently said that climate tech will create 8 to 10 trillion dollar-scale companies. We believe that at least a few of those will be synthetic biology companies. You may be starting one of those companies right now—we’d love to help you accelerate your climate tech R&D with the tools of our platform. Reach out!

Improving Production Efficiency for Vibrant Food Colors with Phytolon

Phytolon and Ginkgo aim to leverage cell programming to produce vibrant betalain pigments across the full yellow-to-purple spectrum.

Scientists have developed hundreds of artificial food dyes by using the tools of synthetic chemistry to convert petrochemical sources into a wide range of colors. While artificial dyes are visually appealing and cheap to manufacture, many have been banned in food and feed due to health concerns. But now, the tools of synthetic biology offer an opportunity to tap into the vibrant colors of nature to produce more sustainable, yet equally vibrant, colors.

What if you could grow sustainable, vibrant dyes?

As consumers increasingly seek out more sustainable and nature-derived products, the food industry is working to find food colors that have equivalent pigment vibrancy to those found in petrochemical-based dyes but which come from biological sources. Phytolon, a growing startup company making natural food colorants, announced a partnership with Ginkgo today to produce vibrant cultured food colors via synthetic biology.

Phytolon has developed a proprietary process using precision fermentation of certain yeast strains to produce betalain pigments—red and yellow pigments naturally found in plants like beets and cactus fruit. Phytolon and Ginkgo are partnering with the goal of maximizing the production efficiency of purple and yellow betalain-producing strains to enable the creation of colors across the full “yellow-to-purple” spectrum. Under this partnership, Phytolon is leveraging Ginkgo’s ability to engineer biology at scale to work together on the production of these betalain pigments. The project aims to help maximize the business opportunity of Phytolon’s vibrant colors for applications in the food and cosmetics industries.

Synthetic biology helps make it possible to produce nature’s wide range of colors at scale.

“We’re excited to work with Ginkgo to develop natural food colors that can potentially outperform conventional artificial dyes in cost and performance,” says Dr. Tal Zeltzer, co-founder and CTO of Phytolon. “We believe biotechnology makes it possible to produce a wider range of colors than ever before that may outperform current benchmark colorants, and we look forward to building products that may meet and even exceed consumer expectations for healthier, sustainable foods, all while aiming to maintain industry requirements for high quality and cost-efficiency.”

We love enabling growing startups like Phytolon through our platform, using biotechnology to challenge industry norms and attempt to build a fundamentally better product than what’s on the market today. The planet needs new sustainable solutions, and we are excited to partner with Phytolon to support a more sustainable food system.

Find the full press release here along with all of the latest news from the Ginkgo team.

New Platform Venture: Arcaea

The products we traditionally use for personal hygiene and beauty can have large ecological impacts. Many of them use chemicals that are byproducts of fossil fuels or harvest ingredients from threatened or endangered ecosystems. What if we could grow the things that make us feel clean and beautiful, sustainably? Beyond environmental concerns, synthetic biology promises the possibility of products with new functions and a vision of nurturing our personal hygiene and redefining our sense of beauty.

Arcaea, LLC (Ar-kay-uh), incubated on the Ginkgo platform and formed under the name Kalo Ingredients LLC, was launched with the mission to build a new foundation for the beauty industry through expressive biology. The company sees biology as a valuable creative tool for self expression and aims to grow new ingredients and product experiences for beauty through the tools of the synthetic biology ecosystem fostered on the Ginkgo platform. By culturing industry-leading, safe, and sustainable ingredients, Arcaea intends to create a new supply chain for the industry that does not rely on petrochemicals or on harvesting and dwindling natural resources.

By harnessing the power of biology, Arcaea is poised to produce highly sustainable products that can deliver new functionality and performance across skincare, bodycare, haircare, and aesthetics.

The company will be led by Jasmina Aganovic, a chemical and biological engineering graduate from MIT. She brings more than a decade of industry experience translating innovation in beauty through brands and products at various beauty companies, including Fresh and Living Proof and the innovative microbiome beauty company Mother Dirt, which changed the way we think about clean and healthy skin. Jasmina saw the powerful role that biology can play in the cosmetics industry, which prompted her interest in creating tools to better realize its potential. She joined Ginkgo as an Entrepreneur-in-Residence, where she spent the last two years building the foundation for Arcaea.

“Through Arcaea, we see biology as a creative tool that will drive the next generation of products and innovation. We can now access many more molecules on earth ethically and sustainably, and therefore can unlock unlimited and previously unimagined possibilities for beauty,” said Aganovic. “By bringing together new advances in technology with designers, brand builders, and leaders from every point of the supply chain, we can spark a change across the entire ecosystem to create an industry that is reflective of the future we want to see for the industry.”

Arcaea has raised $78 million in Series A funding from a consortium of strategic and financial investors including Cascade Investment L.L.C., Viking Global, CHANEL, Givaudan and Wittington Ventures. This Series A financing round brings together a mix of expertise across the value chain of the industry. It will enable Arcaea to initiate multiple technical programs across key categories in beauty to develop a pipeline of ingredients and brand launches and create a world of previously unimaginable possibilities in beauty, such as: a fragrance that no one on earth has ever smelled before; proteins that can memorize hair styles; contouring through skincare and not just makeup; and biological filters that protect skin from the elements.

“One of the most impactful things we can do at Ginkgo is support entrepreneurs and help them accelerate their timelines to make incredible things happen with biology,” said Jason Kelly, co-founder and CEO of Ginkgo. “We are thrilled to see Arcaea launch and begin its journey to deliver creative solutions to the beauty industry through biology.”

Read the press release here.

New Platform Ventures: Launching Verb Biotics, Ayana Bio

Today we’re announcing the launch of two new companies via the Ferment Consortium: Verb Biotics and Ayana Bio.

Verb—a probiotics innovation company—will focus on identifying and designing new strains of probiotic bacteria with advanced properties for human nutrition, health, and wellness. Ayana plans to support human health and wellness by harnessing bioactive compounds for use as complementary medicine.

Verb Biotics
The probiotics category is a $50B global industry that’s growing rapidly. As awareness and understanding of the human microbiome—the trillions of bacteria that live in and on your body—has grown over the past decade, there’s been tremendous interest in probiotic-enhanced foods, beverages, and supplements. Many existing probiotic products use strains of bacteria common to yogurt and other fermented products, but these strains have a number of challenges including limited shelf life, poor stability, and restrictive metabolic profiles.

Since Ginkgo has significant expertise in the discovery and design of microbes with a wide array of functions, Verb plans to leverage our high-throughput platform to perform sequencing, proteomics and metabolomics analysis, pathway design, cell culturing, and fermentation work in order to improve the design and development of probiotics.

Verb is launching with $30 million in Series A funding provided by Viking Global Investors and Cascade Investment.

Ayana Bio
To address issues ranging from supporting a healthy immune system, to aiding metabolism, to promoting healthy aging, consumers are looking for health products that are complementary to conventional medicine. Two categories of products that offer complementary health products—nutraceuticals and traditional medicines—represent over $400 billion.

The bioactive ingredients that go into products in these categories come from a range of natural sources such as medicinal plants and fungi. However, unsustainable harvesting, variability in the source organisms, and the methods of preparation all contribute to uncertainty around these important molecules and limit the potential for widespread use.

Ayana plans to collaborate with global industry leaders in consumer packaged goods, supplements, specialized nutrition, over-the-counter medicines, and traditional medicines to bring to market standardized bioactives that provide consumers with confidence in quality and reliability. Our cell programming platform will support Ayana’s mission to bring to market high purity, clean and reliable medicinal bioactives in convenient forms.

Ayana is launching with $30 million in Series A funding provided by Viking Global Investors and Cascade Investment.

Ferment Consortium
The Ferment Consortium is a company creation studio that works with Viking Global Investors and Cascade Investment to help incubate, fund, and launch new companies that use cell programming to support human and environmental health and wellbeing. (Psst! If you have a great idea of how to grow the future, Ferment Co would love to hear from you.)

Verb and Ayana join our other Platform Ventures: Joyn Bio, Allonnia, and Motif FoodWorks, which recently raised a $226 million Series B round led by Ontario Teachers Pension Plan and BlackRock.

Producing Rare, Natural Ingredients with Givaudan

Nature creates all kinds of wonderful things that excite our senses: from fragrance and flavor molecules that smell and taste amazing to molecules that make cosmetics and foods have just the right texture. Many of these ingredients are found in very small quantities in the plants and other organisms that produce them. Extracting these valuable ingredients can be costly as well as hard or impractical to scale; they can be subject to supply chain disruptions and are increasingly at risk due to climate change.

Givaudan—the world’s leading flavors, fragrances, and cosmetic ingredients company—has signed a multi-program collaboration with Ginkgo to help address these challenges. Givaudan will leverage our long-established expertise in helping companies develop bio-based products. The goal of the programs will be to produce a number of innovative and sustainable ingredients using fermentation.

Through our work, Givaudan plans to provide a sustainable source of products that are currently only available in minute quantities in nature.

Givaudan will leverage our platform to accelerate the development of new ingredients as well as enhance their existing portfolio. The programs will use the natural world as inspiration to create an expanded creative palette for Givaudan.

We’re excited to work with Givaudan to enhance the palette of ingredients they use to develop their products. We plan to help Givaudan transform even the rarest and most complex nature-inspired ingredients into more sustainable products for consumers. Ginkgo believes that biology has the power to enable better and more sustainable products across many industries: from flavors and fragrances, to pharmaceuticals, to farming, and more.

Allison Haitz, Biotechnology Program Director at Givaudan had this to share about the news: “Givaudan has long prided itself on being a leader in innovation. This collaboration with Ginkgo Bioworks is the latest example of our commitment to offering the highest quality, natural products to our customers around the world. We are excited to use biology to unlock more wonders of nature in a sustainable way.”

The collaboration between Ginkgo and Givaudan spans multiple programs, with the possibility of adding more in the future. Companies across numerous industries use Ginkgo’s platform to find more effective, environmentally friendly ways to create products including food ingredients, flavors, cosmetics, medicines, and more. By enabling the design of organisms that can produce valuable biological products, Ginkgo helps accelerate the development of innovative, bio-based solutions to the world’s most pressing environmental challenges.

Scaled Production of Cultured CBG with Cronos Group

Back in June, we announced that we had launched commercial scale production of cultured CBG and had amended our agreement in order to enable Cronos to commercialize cannabinoids ahead of reaching the originally stated productivity targets. In that press release, we wrote that Cronos Group expected that the final productivity target for CBG will be achieved prior to September 2021.

Today, I’m thrilled to announce that we’ve achieved that productivity target for the commercial-scale production of CBG! Reaching this productivity target for the strain producing the cannabigerolic acid (CBGA) molecule will support Cronos Group’s planned CBG product launch this fall. As a result of achieving this milestone, Cronos Group will issue to Ginkgo approximately 1.5 million common shares.

The CBGA molecule will be the fifth product going to market that has directly utilized the Ginkgo platform.

We’ve previously enabled or improved the commercial production of three cultured ingredients for our partners in the flavors and fragrances industry as well as for Aldevron when we improved the production efficiency for their vaccinia capping enzyme used in mRNA vaccine manufacturing.

Cell programming can enable access to rare and important molecules found in nature, including cannabinoids and many other valuable products. We’re proud to be able to help many different companies across industries develop strategies for using biology to innovate new products. We’re thrilled to see the progress our partnership with Cronos Group has made in the three years we’ve worked together and consider it a demonstration of how much can be accomplished when a leading-edge company leverages our platform.

Optimizing Silk Protein Production with Bolt Threads

We built our cell programming platform to make it easier for people to develop apps with biology. And while we love working on brand new ideas with partners, we also really love helping them improve their existing products and processes to make them more efficient and accessible. This week, we’re thrilled to announce Bolt Threads as our latest partner enhancing an existing product by running a cell program on the Ginkgo platform.

Bolt’s cell program seeks to improve the sustainability, efficiency, and cost effectiveness of their b-silk™ protein manufacturing process by leveraging our expertise in strain engineering.

Bolt is a biotechnology company creating the next generation of advanced materials. Their team of engineers and designers have spent nearly a decade at the forefront of the synthetic biology industry, securing partnerships with consumer brands including Kering, Stella McCartney, Adidas, and Lululemon to bring advanced biological materials to consumers around the globe.

In recent years, Bolt has developed b-silk protein, an innovative ingredient inspired by the strength and elasticity of spider silk. They’ve shown that the protein is able to deliver silk-like softness, provide powerful skin defense, and has the potential to sustainably replace synthetic ingredients—like silicones—in skin and hair care products.

While the protein is currently used in premium product lines like Vegamour, the new cell program will leverage Ginkgo’s strain engineering capabilities to improve their production efficiency of b-silk protein, scaling b-silk protein to more mass availability, and potentially unlocking further applications for the ingredient throughout the clean beauty and personal care industries.

We believe in the power of biology to transform every industry that produces physical goods and have built our platform to enable innovators like Bolt to bring their vision to life.

Launching Commercial Production of Cultured Cannabinoids with Cronos

One of the first commercial applications of cell programming that have launched off our platform is the ability to program brewing yeast so that they produce valuable ingredients during fermentation, essentially “brewing” new ingredients in a process that looks like brewing beer. These cultured ingredients can offer a more accessible and sustainable way to produce a wide array of important products, from fragrances to pharmaceuticals. Our partnership with Cronos Group, an innovative global cannabinoid company, is helping them produce a range of rare and often otherwise inaccessible cannabinoid molecules using this process.

I’m thrilled to share that Cronos is beginning their commercial production of the first such rare cultured cannabinoid product we are enabling for them, CBG. Given the progress of the program already achieved, we are amending our agreement in order to accelerate commercialization, which we hope will facilitate these products being first to market in Canada.

You can read more about our collaboration here, and view the press release here.

New Platform Venture: Introducing Motif

When people talk about the future of food, they often start by talking about how the human population is projected to reach 10 billion people by the year 2050. To feed a rapidly growing population with an expanding middle class on a warming planet, we’ll have to use new technologies and build new systems to grow and distribute food. But whether it’s about choosing our next meal or feeding a growing population, the stories we tell about the future of food are full of impossible tradeoffs between taste, cost, health, and the environment (think Soylent vs. Whole Foods). And when it comes to GMOs specifically, the tradeoff is even more stark. Will it ever be possible for food be sustainable, healthy, delicious, and affordable?

At Ginkgo, we believe that biotechnology is an essential part of the future of food, and we hope that it can give us more options, not fewer. We’re working towards a future where genetic engineering and cultured ingredients can help make foods that are more sustainable, healthier, delicious, and more accessible for everyone. It’s what drives our work with customers in the flavor & fragrance and food industries to make cultured ingredients and the work of Joyn Bio, our joint venture with Bayer engineering microbes for more sustainable agriculture.

Today we’re thrilled to be launching Motif Ingredients, a new company built on Ginkgo’s platform to address one of the biggest challenges and changes emerging for the future of food—protein. Recognizing the benefits to health and sustainability that come from a plant-based diet, consumer demand for complements to animal proteins has exploded in the past few years, for products ranging from oat milk to “bleeding” veggie burgers. Companies ranging from brand new startups to industry giants have rapidly innovated new foods based on alternative proteins, but there’s so much more to do to make these options as healthy, delicious, sustainable, and accessible as they should be. Motif Ingredients will use Ginkgo’s Foundry to discover and develop these necessary new alternative protein ingredients that can be made via fermentation, not animal agriculture.

Motif Ingredients is launching today with $90M in Series A funding from Breakthrough Energy Ventures, Fonterra, Louis Dreyfus Company, and Viking Global Investors. Our investors come from both high tech venture capital and traditional food producers that have been feeding the world for more than a century, all believing in our platform’s ability to deliver more alternatives for everyone’s “food future”. Motif will operate from Ginkgo’s offices in the Boston Seaport and leverage our foundries to discover the next generation of alternative proteins. We’re also excited to welcome industry veteran Jon McIntyre to the team as Motif’s CEO. Formerly the head of R&D at Indigo Ag and prior to that, a Senior VP of R&D at PepsiCo, Jon brings a wealth of experience in global food systems and alternative proteins to Motif.

A platform for discovering the next generation of food proteins

Proteins in animal products like meat, dairy, and eggs are essential for the taste, texture, nutrition, health impact, and overall experience of many foods that we eat. Food proteins have unique structural and functional properties, whether they are egg proteins giving a dessert its fluffy texture, or milk proteins protecting a baby’s digestive system from dangerous bacteria. Motif will make different proteins like these via fermentation of engineered microbes, without animal agriculture, to create a rich palette of alternative protein ingredient options for people developing new foods.

An introduction to Motif’s technology by Karen Ingram

Ginkgo’s platform enables biological engineers to deeply study thousands of different protein options across a vast space of biological diversity, discover the proteins that provide the greatest functional benefit, and increase their accessibility at large scale. There is so much that we don’t yet know about even the most common foods, so the ability to search this breadth of biological diversity is essential. Even in the last 5 years, hundreds of new proteins have been discovered in milk and eggs that confer benefits to people who eat them. With Motif, we’re on a mission to explore all that animal proteins have to offer, to enable the next generation of alternative proteins.

Beyond cow’s milk and hen’s eggs, there are also foods with vital benefits that are impossible to access in large amount sustainably, such as sturgeon eggs, camel milk, and everything in between. Just one year ago, scientists discovered a new protein in platypus milk that has surprising antibiotic properties. Using DNA sequence analysis and synthesis, Motif’s scientists will be able to discover and produce hundreds of proteins from many different animals, to understand how their milk and eggs nourish and sustain life in its earliest stages and identify important new ingredients.

At Ginkgo, we are always learning from the creativity of biology and the full breadth of biodiversity to grow better, more sustainable products. We’re so excited to work with Motif as they look to biodiversity to find the proteins that will enable new creativity in food. We’re thrilled to welcome Motif to our platform and to support the next generation of chefs, food designers, and food visionaries who need new ingredients and tools for the future of food.

For more about Motif, visit their website at motifingredients.com. You can also follow them on Twitter and Instagram, and sign up for their newsletter.